Ovid Therapeutics expands epilepsy development expertise

Ovid Therapeutics (OVID) is expanding its medical and development team with the respective appointments of industry veterans, Manoj Malhotra, M.D., as its Chief Medical Officer and Toshiya Nishi, D.V.M., as its Head of Epilepsy Research. Dr. Malhotra is a neurologist with a specialty in epilepsy. He completed his residency in neurology and his fellowship in neurophysiology at the Cleveland Clinic Foundation and served as the Chief of Neurology at Kaiser Permanente. Immediately prior to joining Ovid, Dr. Malhotra served in the Neurology Business Group at Eisai Pharmaceuticals. Dr. Nishi is a pharmacologist and translational scientist who has led multiple drug discovery programs in neurological disorders and other therapeutic areas. He joins Ovid from Takeda Pharmaceuticals (TAK), where he played a critical role in the invention and development of soticlestat, a small molecule inhibitor of cholesterol 24-hydroxylase.